Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Depreciation and Depletion: 2020-2024

Historic Depreciation and Depletion for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to $79,000.

  • ARS Pharmaceuticals' Depreciation and Depletion rose 141.67% to $29,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $79,000, marking a year-over-year increase of 8.22%. This contributed to the annual value of $79,000 for FY2024, which is 8.22% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Depreciation and Depletion of $79,000 as of FY2024, which was up 8.22% from $73,000 recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Depreciation and Depletion registered a high of $800,000 during FY2021, and its lowest value of $34,000 during FY2022.
  • For the 3-year period, ARS Pharmaceuticals' Depreciation and Depletion averaged around $62,000, with its median value being $73,000 (2023).
  • As far as peak fluctuations go, ARS Pharmaceuticals' Depreciation and Depletion crashed by 95.75% in 2022, and later skyrocketed by 114.71% in 2023.
  • Yearly analysis of 5 years shows ARS Pharmaceuticals' Depreciation and Depletion stood at $637,000 in 2020, then rose by 25.59% to $800,000 in 2021, then plummeted by 95.75% to $34,000 in 2022, then spiked by 114.71% to $73,000 in 2023, then grew by 8.22% to $79,000 in 2024.